On May 29, Bristol Myers Squibb announced that its experimental drug mezigdomide delayed disease progression in a late-stage trial for multiple myeloma patients. The results showed that the drug reduces the risk of disease by 52%. These findings represent a significant advancement in the treatment of this type of cancer.
